PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer

PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer
Product Description

Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinomaup-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer.

It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells and tumor microenvironment TME.

Prestige Biopharma Limited

  • SG
  • 2018
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
Specifications
  • Details
    Novel anti-body drug targeting Pancreatic Cancer
  • Selling Points
    Product Features

Prestige Biopharma Limited

  • SG
  • 2018
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical

More Products from Prestige Biopharma Limited (7)

Prestige Biopharma Limited resources (1)